Artificial Intelligence Assisted Follow Up for Gastrointestinal Disorders and Emotional Well Being
Métricas obtenidas de Google Analytics a partir de octubre de 2024.
Resumen
Introduction: Gastrointestinal disorders involve interacting digestive, emotional, sleep, and behavioral factors requiring longitudinal assessment. Objective: To evaluate 12-week feasibility, engagement, and clinical associations of a mobile AI-driven mental health assistant in adults with gastrointestinal disorders. Methods: This prospective comparative study enrolled 186 Venezuelan adults with irritable bowel syndrome, inflammatory bowel disease, functional dyspepsia, or gastroesophageal reflux disease. Participants were assigned to a mobile AI assistant plus standard medical care (n=94) or standard medical care (n=92). The intervention combined conversational support, journaling, and emotional self-reports with required wearable-based monitoring (e.g., smartwatch and smart ring). Both groups underwent assessment of sleep, resting heart rate, nocturnal heart-rate variability, and daily steps. The primary outcome was symptomatic days per week. GAD-7 and PHQ-9 assessed anxiety and depression; adjusted differences included 95% confidence intervals. Results: Participant retention was 91.5% in the intervention group and 85.9% in the standard medical care group, with fewer symptomatic days, reduced anxiety and depression, and 28 additional minutes of sleep nightly. Resting heartrate decreased by 3.6 beats/min and nocturnal RMSSD increased by 5.1 ms relative to comparison; both confidence intervals excluded zero. Daily-step differences were nonsignificant. Daily check-in completion among enrolled participants was 74.8%. Conclusions: The mobile AI intervention was associated with improvements in gastrointestinal symptoms, emotional outcomes, sleep, and autonomic measures.
ESCUCHE EL RESUMEN HANCIENDO CLIC EN EL IDIOMA DE SU PREFERENCIA:
EspañolEnglish
Portugués
Japones
Palabras clave
Texto completo:
PDFReferencias
Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257-1261. doi:10.1053/j.g astro.2016.03.035.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262-1279.e2. doi:10.105 3/j.gastro.2016.02.032.
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.e5. doi:10.1053/j.gas tro.201 6.02.0 31.
Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380-1392. doi:10.1053/j. gastro.2016.02.011.
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-1688. doi:10.1016/S0140-6736(20)31548-8.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-958. doi:10.1001/jama.2015.0954.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. doi:10.1038/nrdp.2016.14.
Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA. 2021;325(9):865-877. doi:10.1001/jama.2020.22532.
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538.
Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351-1362. doi:10.1136/gutjnl-2017-314722.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755. doi:10.1016/S0140-6736(16)31711-1.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi:10.1016/S0140-6736(16)32126-2.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative. Gastroenterology. 2021;160(5):1570-1583. doi:10 .1053/j.gastro.2020.12.031.
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. doi:10.1038/ajg.20 15.233.
Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in ulcerative colitis. Gut. 2017;66(12):2063-2068. doi:10.1136/ gutjnl-2016-312307.
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-1826.e2. doi:10.1053/j.gastro.2010.11.0 58.
Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-660. doi:10.1053/gast.2000.16484.
Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders. Gastroenterology. 2002;122(4):1140-1156. doi:10.1053/gast.2002.32392.
Hirten RP, Danieletto M, Sanchez-Mayor M, Whang JK, Lee KW, Landell K, et al. Physiological data collected from wearable devices identify and predict inflammatory bowel disease flares. Gastroenterology. 2025;168(5):939-951.e5. doi:10.1053/j.gastro.2024.12.024.
Canali S, Schiaffonati V, Aliverti A. Challenges and recommendations for wearable devices in digital health: data quality, interoperability, health equity, fairness. PLOS Digit Health. 2022;1(10):e0000104. doi:10.1371/journal.pdig.0 000104.
Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for biometric monitoring technologies. NPJ Digit Med. 2020;3:55. doi:10.1038/s41746-020-0260-4.
Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ Digit Med. 2019;2:14. doi:10.1038/s41746-019-0090-4.
Sim I. Mobile devices and health. N Engl J Med. 2019;381(10):956-968. doi:10.1056/NEJMra1806949.
Steinhubl SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med. 2015;7(283):283rv3. doi:10.1126/scitranslmed.aaa3487.
Dorsey ER, Topol EJ. State of telehealth. N Engl J Med. 2016;375(2):154-161. doi:10.1056/NEJMra1601705.
Eysenbach G. CONSORT-EHEALTH: improving and standardizing evaluation reports of web-based and mobile health interventions. J Med Internet Res. 2011;13(4):e126. doi:10.2196/jmir.1923.
Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK; SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat Med. 2020;26(9):1364-1374. doi:10.1038/s41591-020-1034-x.
Cruz Rivera S, Liu X, Chan AW, Denniston AK, Calvert MJ; SPIRIT-AI and CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat Med. 2020;26(9):1351-1363. doi:10.1038/s41591-020-10 37-7.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097. doi:10.1001/archinte.166.10.1092.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.20 01.016009606.x.
Borges Grün T. Estudio sobre depresión y ansiedad mediante el PHQ en Venezuela [dissertation]. Madrid: Universidad Complutense de Madrid; 2017.
Sahbaz S, Cox RB Jr, Montero-Zamora P, Salas-Wright CP, Maldonado-Molina MM, Bates MM, et al. Measuring anxiety among Latino immigrant populations: within-country and between-country comparisons. Assessment. 2024;31(7):1414-1429. doi:10.1177/10731911231223715.
Duran P, Ortega Á, Galban N, Vera I, Díaz A, Navarro C, et al. Psychometric behaviour of the GAD-7 in medical students: structural stability, measurement equivalence and contextual sensitivity. Healthcare (Basel). 2026;14(5):563. doi:10.3390/healthcare14050563.
Errazuriz A, Beltrán R, Torres R, Passi-Solar A. The validity and reliability of the PHQ-9 and PHQ-2 on screening for major depression in Spanish speaking immigrants in Chile: a cross-sectional study. Int J Environ Res Public Health. 2022;19(21):13975. doi:10.3390/ijerph192113975.
Sevilla-Gonzalez MDR, Moreno Loaeza L, Lazaro-Carrera LS, Bourguet Ramirez B, Vázquez Rodríguez A, Peralta-Pedrero ML, et al. Spanish version of the System Usability Scale for the assessment of electronic tools: development and validation. JMIR Hum Factors. 2020;7(4):e21161. doi:10.2196/21161.
Digital Helth Technology Limitada. Apoyai [mobile application listing]. App Store [Internet]. Available from: https://apps.apple.com/ec/app/apoyai/id6786046475
Digital Helth Technology Limitada. ApoyAI [mobile application listing]. Google Play [Internet]. Available from: https://play.google.com/store/apps/details?id=com.apoyai.app
Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258. doi:10.3389/fpubh.2017.00258.
Jang A, Hwang SK, Padhye NS, Meininger JC. Effects of cognitive behavior therapy on heart rate variability in young females with constipation-predominant irritable bowel syndrome: a parallel-group trial. J Neurogastroenterol Motil. 2017;23(3):435-445. doi:10.5056/jnm17017.
Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-922. doi:10.1038/ajg.2010. 480.
DOI: http://dx.doi.org/10.61155/gen.v80i4.846
NUESTROS PATROCINADORES
 |  |  |
ISSN: 0016-3503 e-ISSN: 2477-975X